Immunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients

Human Vaccines

Volumn 6, Issue 9, 2010, Pages 736-744

  Mulens, Vladimir ^b   De La Torre, Ana ^e   Marinello, Patricia ^b   Rodríguez, Ronald ^c   Cardoso, Jorge ^a   Díaz, René ^d   O'Farrill, Miguel ^f   Macias, Amparo ^b   Viada, Carmen ^b   Saurez, Giselle ^b   Carr, Adriana ^b   Crombet, Tania ^b   Mazorra, Zaima ^b   Perez, Rolando ^b   Fernandez, Luis Enrique ^b  

^a Maria Curie Hospital   (Cuba)

^b CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^c NATIONAL INSTITUTE OF ONCOLOGY   (Cuba)

^d Hospital Docente Provincial Vladimir I Lenin   (Cuba)

^e Hospital Celestino Hernandez Robau   (Cuba)

^f Department of Radiation Oncology   (Cuba)

Author keywords

Breast cancer; Cancer vaccine; Clinical trial; Ganglioside; Immunotherapy; NeuGcGM3; Patients

Indexed keywords

CANCER VACCINE; GANGLIOSIDE GM3; MONTANIDE ISA 51; N GLYCOLYLATED GM3 GANGLIOSIDE VERY SMALL SIZE LIPOSOME MONTANIDE ISA 51 CANCER VACCINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER IMMUNIZATION; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN CELL; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; METASTASIS; MULTICENTER STUDY; NEISSERIA MENINGITIDIS; PHASE 2 CLINICAL TRIAL; PROTEOLIPOSOME; RANDOMIZED CONTROLLED TRIAL; SKIN ABSCESS; TREATMENT OUTCOME;

EID: 78649379388     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.9.12571     Document Type: Article

References (37)

1. Gray KL. The Leading Cause of Cancer Death in Women. The Internet Journal of Academic Physician Assistants 2007; 6:1.
2. Colozza M. Achievements in systemic therapies in the pregenomic era in metastatic breast cancer. The Oncologist 2007; 12:253-70.
3. De Leon J, Fernandez A, Mesa C, Clavel M, Fernández LE: Role of tumour associated N. glycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells. Cancer Immunol Immunother 2006; 55:443-50.
4. Marquina G, Waki H, Fernandez LE, Kon K, Carr A, Valiente O, et al. Gangliosides expressed in human breast cancer. Cancer Res 1996; 56:5165-71.
5. Horwacik I. Gangliosides as carbohydrate antigens associated with cancer and their possible use in tumor immunotherapy. Przegl Lek 2004; 61:14-9.
6. + regulatory T cells function. Int Immunol 2008; 20:591-600. [Epub 2008 Feb 29].
7. Carr A, Rodriguez E, Arango MC, Camacho R, Osorio M, Gabri M, et al. Immunotherapy of advance breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine. J Clin Oncol 2003; 21:1015-21.
8. Andreopoulou E, Hortobagy GN. Prognostic factors in metastatic breast cancer: successes and challenges toward individualized therapy. J Clin Oncol 2008; 22:3660-2.
9. Aucouturier J, Ascarateil S, Dupuis L. The use of oil adjuvants in therapeutic vaccines. 8-Aucouturier J, Dupuis L, et al. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev Vaccines 2002; 1:111-8.
10. Osorio M, Gracia E, Rodriguez C, Suarez G, Arango Mdel C, Noris E, et al. Heterophilic NeuGcGM3 ganglioside cancer vaccine in advanced melanoma patients: results of a Phase Ib/IIa study. Cancer Biol Ther 2008; 7:488-95.
11. Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J, Arbushites MC, et al. Phase III, Double-Blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008; 26:5544-52.
12. Guarneri V. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: Impact on patient management. The Oncologist 2008; 13:838-44.
13. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer 2008; 2.
14. Wilking U, Skoog L, Elmberger G, Wilking N, Bergh J. HER2 gene amplification (HER2) and hormone receptor expression (ER/PR) in early (EBC) and metastatic breast cancer (MBC) in the same patients. J Clin Oncol 2007; 25:1023.
15. Broom RJ, Tang P, Simmons C, Bordeleau L, O'Malley FP, Miller N, et al. Changes in estrogen receptor (ER), progesterone receptor (PR) and HER2/neu status with time: Discordance rates between primary and metastatic breast pathology samples. J Clin Oncol 2007; 25:1024.
16. Lower EE, Glass EL, Bradley DA, Blau R, Heffelfinger S. Impact of metastatic estrogen receptor and progesterone receptor status on survival. Breast Cancer Res Treat 2005; 90:65-70.
17. Piccart-Gebhart MJ, Burzykowski T, Buyse M, Sledge G, Carmichael J, Lück HJ, et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol 2008; 26:1980-6.
18. Beslija S, Bonneterre J, Burstein H, Cocquyt V, Gnant M, Goodwin P, et al. Second consensus on medical treatment of metastatic breast cancer. Ann Oncol 2007; 18:215-25.
19. Verma S, Clemons M. First-Line treatment options for patients with HER-2-Negative metastatic breast cancer: The impact of modern adjuvant chemotherapy. The Oncologist 2007; 12:785-97.
20. Al-Batran SE, Bischoff J, von Minckwitz G, Atmaca A, Kleeberg U, Meuthen I, et al. The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: Amulticentre phase II trial. Br J Cancer 2006; 94:1615-20.
21. Aucouturier J, Ascarateil S, Dupuis L. The use of oil adjuvants in therapeutic vaccines. Vaccine 2006; 24:2-44.
22. Aucouturier J, Dupuis L, Deville S, Ascarateil S, Ganne V. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev Vaccines 2002; 1:111-8.
23. Roque-Navarro L, Chakrabandhu K, de León J, Rodríguez S, Toledo C, Carr A, et al. Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity. Mol Cancer Ther 2008; 7:2033-41.
24. Shumway NM, Ibrahim N, Ponniah S, Peoples GE, Murray JL. Therapeutic breast cancer vaccines: a new strategy for early-stage disease. BioDrugs 2009; 23:277-87.
25. Curigliano G, Locatelli M, Fumagalli L, Goldhirsch A. Immunizing against breast cancer: a new swing for an old sword. Breast 2009; 18:51-4.
26. Holmberg LA, Sandmaier BM. Vaccination with Theratope (STn-KLH) as treatment for breast cancer. Expert Rev Vaccines 2004; 3:655-63.
27. Hernández AM, Toledo D, Martínez D, Griñán T, Brito V, Macías A, et al. Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody. J Immunol 2008; 181:6625-34.
28. Ragupathi G, Livingston PO, Hood C, Gathuru J, Krown SE, Chapman PB, et al. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin Cancer Res 2003; 9:5214-20.
29. Krug LM, Ragupathi G, Hood C, Kris MG, Miller VA, Allen JR, et al. Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin. Clin Cancer Res 2004; 10:6094-100.
30. Vangsted A, Drivsholm L, Andersen E, Pallesen T, Zeuthen J, Wallin H. New serum markers for smallcell lung cancer. The ganglioside fucosyl-GM1. Cancer Detect Prev 1994; 18:221-9.
31. Birklé S, Zeng G, Gao L, Yu RK, Aubry J. Role of tumour-associated gangliosides in cancer progression. Biochimie 2003; 85:455.
32. Wiesner DA, Sweeley CC. Circulating gangliosides of breast-cancer patients. Int J Cancer 1995; 3:294.
33. Sorice M, Pavan A, Misasi R, Sansolini T, Garofalo T, Lenti L, et al. Monosialoganglioside GM3 induces CD4 internalization in human peripheral blood T lymphocytes. Scand J Immunol 1995; 41:148.
34. Livingston PO, Ragupati G. Carbohydrate vaccines that induce antibodies against cancer. Previous experience and future plans. Cancer Immunol Immunother 1997; 45:10-9.
35. Livingston PO, Zhang S, Old LJ. Carbohydrate vaccines that induce antibodies against cancer. Rationale. Cancer Immunol Immunother 1997; 45:1-9.
36. Gelderman KA, Tomlinson S, Ross GD, Gorter A. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol 2004; 25:158-64.
37. Takahashi T, Johnson TD, Nishinaka Y, Morton DL, Irie RF. IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients. J Invest Dermatol 1999; 112:205-9.